Clinical Trial Update: A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Onartuzumab with bevacizumab versus bevacizumab alone or onartuzumab alone in recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Onartuzumab (onartuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED